[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355450-105":59,"doc-detail-355450-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","from-mutation-to-treatment-the-dual-role-of-brca1-and-brca2-in-gynecological-malignancy-development-and-management-systematic-review","From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management - systematic review","","The Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2) genes are key tumor suppressors that safeguard genomic stability through homologous recombination repair (HRR). BRCA1/BRCA2 mutations impair HRR, leading to defective repair of double-stranded DNA breaks and downstream transcriptional dysregulation that drives cancer. Such mutations substantially increase lifetime risks of ovarian and breast cancer and contribute to inherited gynecological malignancies. The systematic review evaluates BRCA-driven DNA repair, germline BRCA-mutated testing, targeted therapies including PARP inhibitors, resistance mechanisms, combination strategies, nanotechnology-based delivery, biomarker development, and future CRISPR-based approaches.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-mutation-to-treatment-the-dual-role-of-brca1-and-brca2-in-gynecological-malignancy-development-and-management-systematic-review/355450/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-mutation-to-treatment-the-dual-role-of-brca1-and-brca2-in-gynecological-malignancy-development-and-management-systematic-review/355450.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do BRCA1 and BRCA2 protect genomic stability?","Question",{"text":113,"@type":114},"They produce proteins essential for homologous recombination repair (HRR), accurately repairing double-stranded DNA breaks and preventing error accumulation that could lead to tumor development.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why do BRCA1/BRCA2 mutations increase ovarian and breast cancer risk?",{"text":118,"@type":114},"Mutations hinder HRR, impairing repair of double-stranded DNA breaks and resulting in genomic instability and altered transcriptional control that promotes cancer development.",{"name":120,"@type":111,"acceptedAnswer":121},"What treatments are emphasized for BRCA-deficient gynecological tumors?",{"text":122,"@type":114},"The review focuses on germline BRCA-mutated testing and targeted therapy with PARP inhibitors, along with other options such as chemotherapy and immunotherapy, and it discusses combination approaches and resistance mechanisms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355450,1790465591,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Biochemistry and Biophysics Reports 46 (2026) 102564  \nContents lists available at ScienceDirect  \nBiochemistry and Biophysics Reports  \njournal [homepage:](homepage: www.elsevier.com/locate/bbrep)[ www.elsevier.com/locate/bbrep](homepage: www.elsevier.com/locate/bbrep)  \n| From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review\u003Cbr>David M. Georgya, Hana Nagah Sedeeka, Nawal Essam Abazaa, Seif Eldeen K. Eldeeba, Somaya Mohamed Khamis a, Mai R. Elgamila, Raghda W. Magar b,* \u003Cbr>a Department of Applied Biochemistry and Molecular Biology, Faculty of Science, Mansoura University, Mansoura, Egypt b Transplantation Immunology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>Breast cancer gene 1,2 (BRCA1, BRCA2) Poly (ADP-Ribose) polymerase inhibitors (PARP inhibitors)\u003Cbr>Germline BRCA-mutated (gBRCAm) |  | The Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2) genes are pivotal human tumor suppressor genes that are essential for preserving genomic stability. Mutations in BRCA1 and BRCA2 prevent homologous recombination, which is regulated by cell cycle checkpoints, thereby hindering the repair of double-stranded DNA. The ultimate result of genomic instability is characterized by altered transcriptional control and abnormal expression of essential cell-cycle proteins. As significant genetic factors, any mutations in the BRCA1 and BRCA2 genes substantially elevated a woman's risk of getting ovarian and breast cancer, often resulting in the development of these cancers earlier in life. Treatment of breast and ovarian cancer brought on by BRCA gene mutations focuses heavily on germline BRCA-mutated (gBRCAm) testing, targeted therapies such as Poly (ADPribose) polymerase inhibitors (PARP inhibitors), in addition to other options such as traditional chemotherapy and immunotherapy. This systematic review examines the crucial role of BRCA1 and BRCA2 in DNA repair, as well as how their mutations contribute to the development of inherited gynecological malignancies, and potential treatments targeting BRCA-deficient tumors. Also discusses resistance mechanisms to PARP inhibitors, the potential for combination therapies (PARP inhibitors + immune checkpoint inhibitors), and Advances in nanotechnology-based drug delivery, dynamic biomarker development, and CRISPR-based gene repair for BRCA mutations as future challenges and direction for curable patient. |\n\n1. Introduction  \nBRCA1 and BRCA2 are fundamental human genes acting as tumor suppressors. They produce proteins essential for a precise DNA repair process called homologous recombination repair (HRR) [1]. This pathway has a critical system for accurately repairing double-stranded DNA breaks, which can occur during routine DNA replication or in response to environmental stressors. By ensuring the faithful repair of these potentially damaging lesions, BRCA1 and BRCA2 maintain genomic stability and prevent the accumulation of errors that could lead to uncontrolled cell growth and tumor development [2].  \nBRCA1 and BRCA2, located on chromosomes 17q21 and 13q12, respectively, were discovered in the mid-1990s as the first genes linked to inherited susceptibility for ovarian and breast cancer [3]. While these genes are present in all human beings, mutations in them significantly  \nincrease an individual's risk of developing cancer, leading to Hereditary Breast and Ovarian Cancer (HBOC) syndrome. In addition to early-onset  \nbreast and ovarian cancer, HBOC syndrome is associated with an increased risk of pancreatic, stomach, laryngeal, fallopian tube, and prostate cancer. A lifetime risk of 60–80% for breast cancer and 20–40% for ovarian cancer is associated with the presence of mutations in either BRCA1 or BRCA2 genes [3,4].  \nDeficient DNA repair mechanisms, often caused by mutations in BRC","cbCaimYpQB8EnHed","https://ap.wps.com/l/cbCaimYpQB8EnHed","pdf",2006374,"English","# Introduction\n## BRCA1 and BRCA2 as tumor suppressors and HRR regulators\n## Discovery and hereditary susceptibility (HBOC syndrome)\n## Impact of defective DNA repair and genomic instability\n## HRD beyond BRCA mutations and PARP inhibitor rationale","[{\"question\":\"How do BRCA1 and BRCA2 protect genomic stability?\",\"answer\":\"They produce proteins essential for homologous recombination repair (HRR), accurately repairing double-stranded DNA breaks and preventing error accumulation that could lead to tumor development.\"},{\"question\":\"Why do BRCA1/BRCA2 mutations increase ovarian and breast cancer risk?\",\"answer\":\"Mutations hinder HRR, impairing repair of double-stranded DNA breaks and resulting in genomic instability and altered transcriptional control that promotes cancer development.\"},{\"question\":\"What treatments are emphasized for BRCA-deficient gynecological tumors?\",\"answer\":\"The review focuses on germline BRCA-mutated testing and targeted therapy with PARP inhibitors, along with other options such as chemotherapy and immunotherapy, and it discusses combination approaches and resistance mechanisms.\"}]","From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management - systematic review | PDF",1790118955,35,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/69fb7dcc45967127f45c8dc964111c48.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/a2cfcdb1b61f198a3f25a0270237e417.webp",982,1309]